Avingtrans Plc secure two national contracts to make safe nuclear waste

Avingtrans plc

Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that Stainless Metalcraft (Metalcraft), part of the Group’s Energy and Medical division, has secured two national contracts that aim to make safe nuclear waste for long-term storage of the UK’s legacy of nuclear assets. Together, the contracts (one of which is a new contract and the other an extension to an existing contract) are valued at £14.5m and the additions boost Metalcraft’s forward order book to more than £75m over the next six years.

Metalcraft has been awarded the release of the next production phase of a contract to produce stainless steel waste containers that will be used to store intermediate level legacy waste. Additionally, Metalcraft has secured a contract from a new client to prepare concrete waste containers to support decommissioning of the now-retired fleet of UK nuclear power plants.

Nuclear decommissioning is a demanding but developing market that Metalcraft has specifically targeted in recent years. It has invested £7.5 million in new plant and equipment at its production facility to support the contracts, including modern CNC machine tools and robotic welding machines. Anticipating future demand, Metalcraft has also invested £3.4m in a new training facility to manage the supply of skilled personnel to meet anticipated demands of nuclear decommissioning. It is now ready to increase serial production of nuclear containers that meet rigorous specification criteria and proves the company’s ability to deliver highly specialised contracts.

Austen Adams, divisional managing director of Avingtrans PLC, commented:

“We are proud to be a part of this national mission of utmost importance. Winning these additional contracts is a testament to our production capability in Cambridgeshire and the incredible potential of our team members, who are highly skilled and ready to tackle these new challenges in the future decommissioning market.

“This challenge highlights the finest aspects of UK manufacturing while the benefit of a large forward order book enables us to invest in the people essential to the success of the challenge. We are looking forward to fulfilling these contracts and more to follow.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Avingtrans reports higher interim profit and strong FY26 visibility

Avingtrans PLC reported flat first-half revenue of £78.1m for the six months to 30 November 2025, with adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax rising 27.1% to £5.7m.

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

    Search

    Search